Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Chylomicron retention disease (CRD) is a type of familial hypocholesterolemia characterized by malnutrition, failure to thrive, growth failure, vitamin E deficiency and hepatic, neurologic and ophthalmologic complications.
Features include always present findings: Diarrhea and Hypocholesterolemia; and very common findings: Steatorrhea, Damage to the retina (retinopathy), Fat malabsorption, and Elevated circulating hepatic transaminase concentration. 27 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Digestive system | 8 | Diarrhea, Decreased LDL cholesterol concentration, Vomiting |
Muscles | 3 | Reduced tendon reflexes, EMG: myopathic abnormalities, Myopathy |
Growth and development | 2 | Failure to thrive, Growth delay |
Eyes | 2 | Damage to the retina (retinopathy), Visual impairment |
Brain and nerves | 1 | Intellectual disability |
Lab test results | 1 | Elevated circulating hepatic transaminase concentration |
Metabolism | 1 | Abnormality of vitamin metabolism |
To date, approximately 40 individuals have been identified with biallelic pathogenic variants in SAR1B . The following description of the phenotypic features associated with this condition is based on these reports. Chylomicron retention disease (CMRD) typically presents in infancy as failure to thrive, diarrhea, vomiting, abdominal distention, and malabsorption of fat . Some of the extraintestinal manifestations (e.g., those affecting the eyes, neuromuscular system, and blood) are due to deficiencies of fat-soluble vitamins. Table 2. Chylomicron Retention Disease: Frequency of Select Features in Untreated Individuals Feature | Frequency
In nearly all | Common | Infrequent |
|---|---|---|
No chylomicrons in response to oral fat load | Abdominal distention | Vomiting |
Source: GeneReviews — "Chylomicron Retention Disease"
SAR1B function has not been fully characterized.
Chylomicron retention disease is associated with mutations in the SAR1B gene on chromosome 5.
No genotype-phenotype correlations for SAR1B have been identified.
Source: GeneReviews — "Chylomicron Retention Disease"
No consensus clinical diagnostic criteria for chylomicron retention disease (CMRD) have been published.
CMRD should be suspected in individuals with the following clinical, supportive laboratory, and endoscopic findings.
Clinical findings
Failure to thrive, with diarrhea
Fat malabsorption with steatorrhea
Vomiting
Abdominal distention
Supportive laboratory findings
Source: GeneReviews — "Chylomicron Retention Disease"
Table 3. Genes of Interest in the Differential Diagnosis of Chylomicron Retention Disease
Gene | DiffDx Disorder | MOI | Features of DIffDx Disorder |
|---|---|---|---|
Familial combined hypolipidemia | AR | Low plasma levels of LDL HDL cholesterol | Familial combined hypolipidemia is not assoc w/any clinical symptoms (i.e., no failure to thrive or steatorrhea), plasma triglyceride levels are very low. |
APOB | Biallelic APOB-related familial hypobetalipoproteinemia (FHBL) |
Genetic testing for SAR1B is available. Testing is considered confirmatory for diagnosis.
No approved treatments are currently available for chylomicron retention disease. The disease remains an area of unmet medical need.
Clinical practice guidelines for chylomicron retention disease (CMRD) have been published based primarily on expert opinion .
To establish the extent of disease and needs in an individual diagnosed with CMRD, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended.
Table 4.
Recommended Evaluations Following Initial Diagnosis in Individuals with Chylomicron Retention Disease
System/Concern | Evaluation | Comment
| Growth parameters | To assess for poor growth
| Plasma lipid profile:
Total cholesterol
LDL cholesterol
HDL cholesterol
Triglyceride
Apo B
Apo A-I
| Normal TG levels are characteristic, while other lipid/lipoprotein variables are usually depressed.
Serum concentration of fat-soluble vitamins (A, D, E) INR |
Liver transaminases (AST ALT), GGT, total bilirubin, alkaline phosphatase |
Abdominal ultrasound, typically after age 10 yrs | To evaluate for hepatomegaly steatosis
Referral to nutritionist | To provide dietary advice re low-fat diet
| INR | Prolongation of INR may result from vitamin K deficiency.
Consider CBC. | Anemia mild acanthocytosis has only rarely been reported.
| Consider referral to ophthalmologist, typically after age 10 yrs, unless there are clinical signs/symptoms before age 10 yrs. | • To evaluate visual acuity for baseline fundus exam
Consider visual evoked potential electroretinography in those w/concerning symptoms.
Source: GeneReviews — "Chylomicron Retention Disease"
Avoid fatty foods, particularly those rich in long-chain fatty acids.
Source: GeneReviews — "Chylomicron Retention Disease"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "Chylomicron Retention Disease"
View trials for chylomicron retention disease
Table 6.
Recommended Surveillance for Individuals with Chylomicron Retention Disease
Frequency | Evaluation1
| • Measurement of growth parameters
Eval of digestive neurologic symptoms
Eval of dietary fat content compliance
Laboratory investigations:
Lipid profile2
Liver function tests (AST, ALT, GGT, total bilirubin, alkaline phosphatase)
Vitamins A, D, E; INR
CBC
Every 3 yrs
after age 10 yrs | • Liver ultrasound
Neurologic: clinical exam, creatine kinase, electromyography
Ophthalmologic: eval of fundus, assessment of color vision, visual evoked potentials, electroretinography
DXA scan (whole-body bone mineral content)
Every 3-5 yrs
in adults | Echocardiography (ejection fraction)
ALT = alanine aminotransferase; AST = aspartate aminotransferase; CBC = complete blood count; DXA = dual-energy x-ray absorptiometry; GGT = gamma-glutamyl transferase; INR = international normalized ratio
1. Surveillance of CMRD is based on that recommended for abetalipoproteinemia .
2. To include total, LDL, and HDL cholesterol levels and measurement of triglycerides
Source: GeneReviews — "Chylomicron Retention Disease"
Phenotype severity distribution: 2 always present features, 4 very common features, 6 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for chylomicron retention disease.
7 publications have been identified in PubMed for chylomicron retention disease. Research spans Case Report / Case Series (43%), Basic Science / Preclinical (29%), and Review / Meta-Analysis (14%).
Galimberti G (2026). [PMID: 41031964](https://pubmed.ncbi.nlm.nih.gov/41031964/). *Pain*. [Gene Therapy / Novel Therapeutics]
Liu B (2026). [PMID: 41767779](https://pubmed.ncbi.nlm.nih.gov/41767779/). *Frontiers in pediatrics*. [Case Report / Case Series]
Levy E (2024). [PMID: 39062121](https://pubmed.ncbi.nlm.nih.gov/39062121/). *Biomedicines*. [Basic Science / Preclinical]
Sunkoj Y (2024). [PMID: 38749523](https://pubmed.ncbi.nlm.nih.gov/38749523/). *BMJ case reports*. [Case Report / Case Series]
Peñafiel-Freire DM (2024). [PMID: 39332967](https://pubmed.ncbi.nlm.nih.gov/39332967/). *Anales de pediatria*. [Case Report / Case Series]
Tang VT (2024). [PMID: 38687799](https://pubmed.ncbi.nlm.nih.gov/38687799/). *Proceedings of the National Academy of Sciences of the United States of America*. [Basic Science / Preclinical]
Zhang YQ (2024). [PMID: 38763880](https://pubmed.ncbi.nlm.nih.gov/38763880/). *Zhonghua er ke za zhi = Chinese journal of pediatrics*. [Review / Meta-Analysis]
Data assembled from 7 of 12 sources · Last updated Sep 19, 2026, 7:54 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about chylomicron retention disease
AR |
May be clinically similar (failure to thrive, steatorrhea) |
Abetalipoproteinemia | AR | May be clinically similar (failure to thrive, steatorrhea) | In abetalipoproteinemia, LDL cholesterol is absent triglyceride is very low to absent; ophthalmologic manifestations are variable; most prominent is acquired atypical pigmentation of retina. |
PCSK9 | Hypocholesterolemia w/ LDL cholesterol (OMIM 607786) | AD | Low plasma levels of LDL cholesterol |
Source: GeneReviews — "Chylomicron Retention Disease"